2013
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. The Lancet Oncology 2013, 14: e302-e309. PMID: 23816296, DOI: 10.1016/s1470-2045(13)70085-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabDrug DesignDrug Resistance, NeoplasmErbB ReceptorsHead and Neck NeoplasmsHistone Deacetylase InhibitorsHumansMolecular Targeted TherapyPapillomaviridaeProtein Kinase InhibitorsProto-Oncogene Proteins c-metReceptor, ErbB-2Signal TransductionTreatment OutcomeConceptsHPV-negative headNeck cancerHuman papillomavirusEGFR inhibitionSingle-agent cetuximabLow cure rateMonoclonal antibody cetuximabActive therapyCytotoxic chemotherapyDisease survivalCure rateMechanisms of resistanceAntibody cetuximabResponse rateCetuximabEGFRNovel targetReceptor tyrosine kinasesCancerTherapyHistone deacetylaseChemotherapyHabitual exposureModest effectNuclear functions
2006
Novel targets in pancreatic cancer: focus on future paths to therapy
Cohen SJ, Burtness BA. Novel targets in pancreatic cancer: focus on future paths to therapy. Expert Opinion On Therapeutic Targets 2006, 10: 771-775. PMID: 16981833, DOI: 10.1517/14728222.10.5.771.Peer-Reviewed Original ResearchConceptsPancreatic cancerNew therapeuticsRational clinical trialsTobacco-related malignanciesDismal overall survivalPancreatic cancer pathogenesisPreclinical model systemsAdvanced diseaseOverall survivalCytotoxic therapyHER2 inhibitionClinical trialsTherapeutic increasesClinical dataClinical testingTissue factorNew casesCancer pathogenesisNovel targetCancerNew targetsTherapyEqual numberTherapeuticsMalignancy